About Takeda

Takeda is a global values-based, R&D-driven biopharmaceutical leader committed to creating better health for people and a brighter future for the world. For more than 240 years, Takeda has focused on delivering transformative treatment and significantly increasing the value that we bring to society.


Our values of Takeda-ism are brought to life through actions based on:

Putting the patient first

Building trust with society

Reinforcing our reputation

Developing a sustainable business

About Takeda

Takeda is a leading global biopharmaceutical company with a more than 240-year history, a values-based, Research & Development (R&D)-driven company with approximately 47,000 employees in 80 countries. We strive to address unmet medical needs by delivering life-transforming or life-saving medicines and vaccines around the world. Our strong commitment to putting patients first is what drives our scientific discoveries and operational excellence, and helps us solve unmet medical needs. Takeda-ism, in turn, has always been our unique compass on this journey. Its timeless values – Integrity, Fairness, Honesty and Perseverance – define who we are. We bring Takeda-ism to life through actions based on Patient-Trust Reputation-Business, in that order, to form a philosophy that defines who we are, what we do and why it matters.

Over 60 years in Brazil

In Brazil, Takeda is among the top 10 operactions in the world.

Jaguariuna plant is the first #landfillfree among all Takeda plants in the world.

Committed to Diversity, Equity & Inclusion through its seven working committees.

Products in the Brazilian market


Drugs commercialized in Brazil


manufactured or packaged in the country

Main drugs available in Brazil

Services and Support for


About 3100

Active patients undergoing treatment in the Patient Support Program (PSP)*

More than 1,300 tests performed for rare and complex diseases;

Takeda Contribution to Physicians and Patients in 2020:

35 enrolled

in the patient aid program (PAP)*

Support for 43 projects from 20 patient associations from all over Brazil.

Diversity, Equity and Inclusion


of all employees are women


of all leadership positions are occupied by women

Expansion of the diversity program, totalizing:


New factory diversity groups




Public commitments internally encouraged

Takeda In Brazil


Administrative office
in Sao Paulo (SP)

in Itapevi (SP)

Factory in
Jaguariuna (SP)




applications (either filed or granted) in the country

Corporate social


Employees took part
in volunteer activities


Items donated to
several institutions

among blood, hair, school supplies, easter eggs, toys, clothes, hygiene items and Christmas bags


DirecteIy impcated lives via
donations and incentive laws


Indirectely impcated lives

Envirornmental Responsability


of the factory employees are certified in envirornmetal trainings


of the energy comes from renewable sources


of the waste produced is treated internally alongside the "Zero Aterro" Project

Silver Level LEED for Neighborhood Development

2022 Best in Building Health Leadership Awards among all Fitwel certified projects

ISO 14001:2015 since 2013

R&D innovative portfolium

Dengue Overview

Dengue is a risk for about half of the world population


Countries classify it as a public health issue

infections have been on a rising trend on the american continent


from the public funds are spent every year to cover the damages caused by the disease PLACEHOLDER

There are four dengue stereotypes: DENV-1, DENV-2, DENV-3, and DENV-4. For this reason, people can be infected with dengue multiple times in their life. Different stereotypes are also associated with prevalence of specific symptoms.

Ways of Transmission

Mosquito bites

The most common form of dengue transmission is through infected female mosquitoes bites, primarily the Aedes aegypti mosquito.

Maternal transmission

There is evidence of maternal transmission to babies. Although vertical transmission rates are low, linked to the timing of the infection during pregnancy.

Infected biological material

DENV can also be transmitted through blood products, organ donation, and transfusions in rare cases.

Dengue in Brazil

+16 mi

possible infections





(2002-2022) data from Sinan, SVS, SIH, SAS and MS

Adults over 29 and elderly population comprise 60% of the hospitalization cases

~35% being from the 29 to 60 years old age group and ~25% from the 60+ age group

2022 data from SIH, SAS and MS

2022 data from SVS' epidemiologic bulletin
* Cases per 100,000 people


severe cases


cases with alarming signs

2022 data from SVS' epidemiologic bulletin

severe cases are characterized by: bleeding, organ dysfunctions or plasma extravasation

Alarming signs are characterized by: continuous intense abdominal pain, persisting vomit, liquid accumulation (ascitis, pleural stroke and pericardial stroke), postural hypotension and/or lipothymia, lethargy and/or irritability, hepatomegaly of over 2cm under the costal margin, mucous membranes bleeding, progressive rising of the hematocrit

About QDENGA® (Tetravalent Dengue Vaccine [Live, Attenuated])

Proposed Commercial Name



2 doses (0, 3 months)

Route of Administration


Proposed expiration date

18 months (3-8ºC)

ANVISA registry request

April 26, 2021


Lyophilized powder with diluent (37 mM sodium chloride) in vial or pre-filled syringe

Proposed indication

Qdenga® is indicated for the prevention of dengue in individuals from 4 years old

QDENGA® (TAK-003) is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four dengue virus serotypes and is designed to protect against any of these serotypes.

In Brazil, QDENGA is indicated for the prevention of dengue disease caused by any dengue virus serotype in individuals from 4 to 60 years of age and should be administered subcutaneously as a 0.5 mL dose at a two-dose (0 and 3 months) schedule pursuant to approved dosing regimen. 

The approval of QDENGA is based on results across 19 Phase 1, 2 and 3 trials with more than 28,000 children and adults, including four and a half years of follow-up data from the global, pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. The TIDES trial met its primary endpoint of overall vaccine efficacy (VE) by preventing 80.2% of symptomatic dengue cases 12 months after vaccination.¹ In addition, TAK-003 met its key secondary endpoint by preventing 90.4% of hospitalizations 18 months after vaccination.⁵ Efficacy varied by serotype (DENV-1 – 4).² ³ The TIDES exploratory analyses showed that throughout the four and a half-year study follow-up, TAK-003 prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases in the overall study population, which included both seropositive and seronegative individuals.³ TAK-003 has been generally well tolerated, with no evidence of increased incidence of severe disease in baseline sero-negative vaccine recipients, and no important safety risks identified, to date.⁴

1 Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019; 2019;381:2009-2019.
2 Biswal S, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo controlled, phase 3 trial. Lancet. 2020. 2020;395:1423-1433.
3 Tricou, V. Efficacy and Safety of Takeda’s Tetravalent Dengue Vaccine Candidate (TAK-003) After 4.5 Years of Follow-Up. Presented at the 8th Northern European Conference of Travel Medicine; June 2022.
4 Huang CY-H, et al. Genetic and phenotypic characterization of manufacturing seeds for tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. 2013;7:e2243.

Main differences between QDENGA® and DengVaxia®



1. Takeda. DEN-301 data on file. 2021; 
2. Sridhar S, et al. N Engl J Med 2018;379:327–340.

PAHO – Pan American Helath Organization

SEARO – World Health Organization South-East Asia Region

WPRO – WHO Western Pacific Region

EURO – Europe (travel-associated cases)


*Preliminary data, subject to change. Source: Sinan/SVS/MS. Base exported on 07/14/2022

*Source: Notifiable Diseases Information System (Sinan/SVS).

Data updated and expanded from http://plataforma.saude.gov.br/anomalias-congenitas/boletim-epidemiologico-SVS-33-2020.pdf

© 2023 Kasznar Leonardos